Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Revance Therapeutics, Inc. (NASDAQ: RVNC).

Full DD Report for RVNC

You must become a subscriber to view this report.


Recent News from (NASDAQ: RVNC)

Week In Review: China Pharmas Announce Deals Worth $1.5 Billion
Deals and Financings WuXi AppTec (SHA: 603259), China's largest CRO/CMO, completed a $1 billion IPO on the Hong Kong markets, pricing the offering in the middle of the expected range. In May, WuXi became a public company by completing a $328 million IPO in Shanghai. Since the offering, the...
Source: SeekingAlpha
Date: December, 10 2018 00:48
Revance to Participate in the Credit Suisse Healthcare Conference
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Credit Suisse Healthcare Conference in Phoenix, AZ. President an...
Source: Business Wire
Date: November, 07 2018 16:05
Revance Therapeutics, Inc. (RVNC) CEO Daniel Browne on Q3 2018 Results - Earnings Call Transcript
Revance Therapeutics, Inc. (RVNC) Q3 2018 Earnings Conference Call November 1, 2018, 16:30 ET Executives Jeanie Herbert - Senior Director of IR & Corporate Communications Daniel Browne - Co-Founder, CEO, President & Director Cyril Allouche - Head of Finance, Interim Princ...
Source: SeekingAlpha
Date: November, 01 2018 23:46
Revance Therapeutics beats by $0.12, beats on revenue
Revance Therapeutics (NASDAQ: RVNC ): Q3 GAAP EPS of -$0.91 beats by $0.12 . More news on: Revance Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: November, 01 2018 16:16
Revance Releases Third Quarter 2018 Results
- Chief Financial Officer Toby Schilke and Interim Head of Commercial - Aesthetics & Therapeutics Dustin Sjuts to assume roles on November 5 - Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic a...
Source: Business Wire
Date: November, 01 2018 16:05
Revance Therapeutics to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018
-Conference Call Scheduled for Thursday, November 1, 2018 at 4:30pm ET- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will release second quar...
Source: Business Wire
Date: October, 18 2018 16:05
Investor Expectations to Drive Momentum within Materion, Iridium Communications, Natural Health Trends, Revance Therapeutics, Baxter International, and Alexion Pharmaceuticals - Discovering Underlying Factors of Influence
NEW YORK, Oct. 11, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Materion Corporation (NYSE:MTRN), Iridium Communications Inc (NASDAQ:I...
Source: GlobeNewswire
Date: October, 11 2018 09:00
Revance Therapeutics Appoints Tobin C. Schilke as Chief Financial Officer
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that it has strengthened its leadership team with the appointment of Tobin C. Schilke as chief financial officer, effective N...
Source: Business Wire
Date: October, 11 2018 08:30
New Research Coverage Highlights Titan International, Revance Therapeutics, Ryerson Holding, Iridium Communications, Chase, and Peoples - Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Titan International, Inc. (NYSE:TWI), Revance Therapeutics, Inc. (NASDAQ:...
Source: GlobeNewswire
Date: August, 07 2018 07:30
Revance Therapeutics' (RVNC) CEO Dan Browne on Q2 2018 Results - Earnings Call Transcript
Revance Therapeutics, Inc. (RVNC) Q2 2018 Earnings Conference Call August 2, 2018, 4:30 pm ET Executives Jeanie Herbert - Senior Director, IR & Corporate Communications Dan Browne - President & CEO Cyril Allouche - Interim Principal Financial Officer & Principal Accou...
Source: SeekingAlpha
Date: August, 04 2018 04:43

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0826.9527.3527.8026.925131,520
2018-05-2131.0530.3531.2530.20154,584
2018-05-1830.7030.8531.7030.70201,700
2018-05-1730.4030.8030.8030.05152,771
2018-05-1629.4530.4531.3529.25250,913

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0770,414107,90665.2549Short
2018-12-06115,324208,65755.2697Short
2018-12-04427,839543,51378.7173Short
2018-12-0323,94740,97858.4387Short
2018-11-307,07924,86428.4709Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RVNC.


About Revance Therapeutics, Inc. (NASDAQ: RVNC)

Logo for Revance Therapeutics, Inc. (NASDAQ: RVNC)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: RVNC)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 11 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 08 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 19 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: April, 10 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: April, 09 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: March, 20 2018
      Prospectus filed under Rule 424(b)(5)
      Filing Type: 424B5Filing Source: edgar
      Filing Date: March, 13 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 13 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 02 2018

       

       


      Daily Technical Chart for (NASDAQ: RVNC)

      Daily Technical Chart for (NASDAQ: RVNC)


      Stay tuned for daily updates and more on (NASDAQ: RVNC)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: RVNC)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RVNC is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of RVNC and does not buy, sell, or trade any shares of RVNC. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/